Synmosa Biopharma Corp Statistics
Synmosa Biopharma Corp (4114) Stock Statistics & Valuation Metrics
Total Valuation
Synmosa Biopharma Corp has a market cap or net worth of TWD 14.62B. The enterprise value is TWD 18.79B.
- Market Cap
- TWD 14.62B
- Enterprise Value
- TWD 18.79B
Share Statistics
Synmosa Biopharma Corp has 550,886,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 550,886,660
- Owned by Insiders
- ―
- Owned by Institutions
- 3.13%
Financial Efficiency
Synmosa Biopharma Corp’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 4.75%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 4.75%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 12.50M
- Profits Per Employee
- 1.66M
- Employee Count
- 495
- Asset Turnover
- 0.44
- Inventory Turnover
- 1.67
Valuation Ratios
The current PE Ratio of Synmosa Biopharma Corp is 17.78. Synmosa Biopharma Corp’s PEG ratio is -28.28.
- PE Ratio
- 17.78
- PS Ratio
- 2.28
- PB Ratio
- 1.56
- Price to FCF
- 100.70
- Price to Operating Cash Flow
- 37.96
- PEG Ratio
- -28.28
Income Statement
In the last 12 months, Synmosa Biopharma Corp had revenue of 6.19B and earned 821.85M in profits. Earnings per share was 1.66.
- Revenue
- 6.19B
- Gross Profit
- 2.54B
- Operating Income
- 778.48M
- Pretax Income
- 799.64M
- Net Income
- 821.85M
- EBITDA
- 1.12B
- Earnings Per Share (EPS)
- 1.66
Cash Flow
In the last 12 months, operating cash flow was 355.79M and capital expenditures -204.80M, giving a free cash flow of 150.99M billion.
- Operating Cash Flow
- 355.79M
- Free Cash Flow
- 150.99M
- Free Cash Flow per Share
- 0.31
Dividends & Yields
Synmosa Biopharma Corp pays an annual dividend of ―, resulting in a dividend yield of 3.12%
- Dividend Per Share
- ―
- Dividend Yield
- 3.12%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.00%
- Earnings Yield
- 5.79%
Stock Price Statistics
- Beta
- 0.31
- 52-Week Price Change
- -12.32%
- 50-Day Moving Average
- 29.37
- 200-Day Moving Average
- 28.79
- Relative Strength Index (RSI)
- 20.94
- Average Volume (3m)
- 869.93K
Important Dates
Synmosa Biopharma Corp upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Synmosa Biopharma Corp as a current ratio of 2.95, with Debt / Equity ratio of 28.71%
- Current Ratio
- 2.95
- Quick Ratio
- 1.98
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- 0.56
- Interest Coverage Ratio
- 12.54
Taxes
In the past 12 months, Synmosa Biopharma Corp has paid 181.22M in taxes.
- Income Tax
- 181.22M
- Effective Tax Rate
- 0.23
Enterprise Valuation
Synmosa Biopharma Corp EV to EBITDA ratio is 16.19, with an EV/FCF ratio of 110.59.
- EV to Sales
- 2.50
- EV to EBITDA
- 16.19
- EV to Free Cash Flow
- 110.59
- EV to Operating Cash Flow
- 46.93
Balance Sheet
Synmosa Biopharma Corp has TWD 2.78B in cash and marketable securities with TWD 3.36B in debt, giving a net cash position of -TWD 578.33M billion.
- Cash & Marketable Securities
- TWD 2.78B
- Total Debt
- TWD 3.36B
- Net Cash
- -TWD 578.33M
- Net Cash Per Share
- -TWD 1.05
- Tangible Book Value Per Share
- TWD 19.04
Margins
Gross margin is 40.66%, with operating margin of 10.70%, and net profit margin of 11.61%.
- Gross Margin
- 40.66%
- Operating Margin
- 10.70%
- Pretax Margin
- 11.65%
- Net Profit Margin
- 11.61%
- EBITDA Margin
- 15.44%
- EBIT Margin
- 11.46%
Analyst Forecast
The average price target for Synmosa Biopharma Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 11.40%
- EPS Growth Forecast
- 9.36%
